Peptides copied from a mitochondrial DNA helicase kill multidrug-resistant bacteria — in lab tests
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
Two short peptides designed from the mitochondrial targeting sequence of the Twinkle DNA helicase (from an Antarctic fish) killed a range of bacteria — including multidrug-resistant strains — in laboratory tests, at bactericidal concentrations of 0.5 to 32 micromolar (ACS Omega, November 3, 2026). The work is an in-silico and in-vitro proof of concept; no infection model in animals and no human testing was reported.
The design brief sounds like a riddle: take the address label a cell uses to ship a protein into its mitochondria, and turn it into a weapon against bacteria. It works precisely because mitochondria and bacteria are ancient relatives — the label fits both envelopes.
Why start from a mitochondrial protein?
Twinkle is the helicase that unwinds mitochondrial DNA so it can be copied and maintained; its human version is essential, and Twinkle defects cause mitochondrial disease. Like most mitochondrial proteins, Twinkle is made in the cytosol and imported, guided by an N-terminal targeting sequence — typically a short, positively charged, helix-forming stretch. Those are exactly the physical features of antimicrobial peptides, which kill bacteria by disrupting their membranes. The team mined the Twinkle targeting sequence of the Antarctic fish Notothenia coriiceps and optimized two 18-residue candidates in silico.
How well did the peptides kill?
Both TAMP1 and TAMP2 adopted stable amphipathic alpha-helical conformations. TAMP2, the optimized derivative, retained activity against an extended panel that included spoilage organisms, foodborne pathogens and multidrug-resistant bacteria, across Gram-positive and Gram-negative species, with minimum bactericidal concentrations spanning 0.5 to 32 micromolar — the low end of that range (0.5 to 1 micromolar) against the initial spoilage panel. Biophysical measurements and simulations pointed to strong binding to bacterial-membrane mimics, consistent with a membrane-disruption mechanism, and the authors report no toxic effects in the assays they ran.
What stands between this and an antibiotic?
The usual peptide gauntlet: stability in blood and tissue, selectivity for bacterial over human membranes at real-world doses, manufacturing cost, and efficacy in an actual infected animal — none of which this proof-of-concept attempts. Antimicrobial peptides have a long history of brilliant lab results and difficult translations. The mitochondrial connection here is the design origin, not a therapeutic effect on mitochondria: the peptides target bacteria, full stop.
Frequently asked questions
What is Twinkle?
Twinkle is the helicase that unwinds mitochondrial DNA during replication and maintenance. Its mitochondrial targeting sequence — the short peptide 'address label' that routes it into mitochondria — was the template for the antibacterial peptides in this study.
How potent were the peptides?
The optimized peptide TAMP2 killed spoilage, foodborne and multidrug-resistant bacteria in laboratory assays at minimum bactericidal concentrations of 0.5 to 32 micromolar, with the strongest activity (0.5 to 1 micromolar) against the initial spoilage panel.
Are these peptides a new antibiotic I can get?
No. This is an early laboratory proof of concept — computer design plus dish-based killing assays. There is no animal infection study, no human trial and no product.
Where the evidence stands
- Established: That mitochondrial targeting sequences and antimicrobial peptides share amphipathic, positively charged helix chemistry is established biophysics, rooted in mitochondria's bacterial ancestry.
- Preliminary: TAMP1/TAMP2's antibacterial activity: one in-silico plus in-vitro study. Potency in dishes does not predict a usable drug.
- Absent: Any test in an infected animal model or in humans, and any pharmacology (stability, distribution, dosing).
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.